ArticleKidney research and clinical practice2026
Effectiveness and safety of denosumab on osteoporosis treatment in kidney transplant recipients.
Article in Kidney research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Denosumab for kidney transplant recipients: clinical value and unresolved questions.Kidney research and clinical practice · 2026Article
- Decoding the secretory blueprint of bone healing: from gradients to regeneration.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDenosumab has been reported to improve bone mineral density (BMD), but the clinical impact of denosumab on osteoporosis in kidney transplant recipients (KTRs) remains controversial.
methodsWe analyzed 98 KTRs who used denosumab from 2018 to 2023. We investigated the change in BMD, laboratory findings, complications of denosumab, fracture risk assessment tool (FRAX) score, acute rejection within 1 year, and graft failure.
resultsMean T-scores at 1 year after denosumab were significantly increased compared to mean T-scores pre-denosumab at the femur neck and spine area, respectively (-2.68 ± 0.68 vs. -2.81 ± 0.68, p < 0.001; -2.78 ± 0.96 vs. -3.21 ± 1.00, p < 0.001). The levels of calcium and phosphorus significantly decreased and those of vitamin D significantly increased at 1 year after denosumab, but there were no significant differences in parathyroid hormone, allograft function, and tacrolimus trough level. There were no recurrent fractures among 12 KTRs with a history of fracture, but three de novo fractures happened. Cardiovascular events occurred in three patients. Denosumab-induced hypocalcemia developed in eight patients, but severe hypocalcemia was observed in only one patient. Acute kidney injury did not happen. Urinary tract infection (UTI) occurred in 17 patients. Arthralgia occurred in four patients. FRAX score was significantly decreased after denosumab. Acute rejection within 1 year after denosumab developed in three patients. There was no graft failure.
conclusionThe use of denosumab in KTRs is effective and safe for the treatment of osteoporosis and prevention of fracture, but it should be carefully monitored for complications, especially UTI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.